ICON has acquired PRA Health Sciences, creating the world's most advanced healthcare intelligence and clinical research organisation. With a singular focus on high quality and efficient clinical trial execution, from Phase 1 to post-approval studies, this strategic acquisition beings specific opportunities for customers, including:
Scale: With broader and deeper consulting, clinical and commercial services portfolio, geographic footprint, depth of therapeutic expertise, and expansive data driven healthcare technology, we will deliver enhanced globally scaled expertise & solutions for all customers. ICON is now:
- World leader in Functional Service Provision (FSP)
- Global number 2 in full service Ph 2/3 clinical research
- Global number 2 in Early Phase clinical research
- Global number 3 in Late Phase & RWE
- Global number 4 in Central & Specialty Laboratory Services
Focus: ICON has a singular focus on clinical research and commercialisation, leveraging transformational technology and innovation to execute clinical trials from Phase 1 to post-approval studies, with the highest quality, expertise and speed. With no ownership from a parent organisation with different business lines or models, and no distractions from ‘near adjacencies’, we are completely committed to achieving clients’ clinical development programs.
Continuity and delivery: Both organisations have a solid track record of delivery and highly experienced management teams who have a strong history integrating successful businesses. We have launched a comprehensive integration management office, with senior members from ICON and PRA represented in every workstream on the integration planning team, to ensure minimal disruption to client service delivery and effective, gradual integration of both organisations.
Speed to market: Our extensive services portfolio, digital and data technology capabilities, and enhanced access to more diverse patient populations, will be combined with flexible delivery approaches and partnership models – all with the aim of reducing development time and cost.
Flexible partnership models: ICON now has partnerships with a majority of world’s top biopharma companies, as well as thousands of biotech clients worldwide. ICON is now the global leader in Functional Service Provision and a top global provider of full service clinical research. Regardless of the size of your organisation or your project, we will work your way.
Differentiated DCT platform, healthcare intelligence and technology: Combining PRA’s mobile health, commercial connected health platforms, real world data and information solutions, together with ICON’s global site network, home health services and wearables expertise, enables ICON to deliver differentiated de-centralised and hybrid trial solutions to meet growing customer needs.
Access to patients: The combinations of ICON’s global site network (Accellacare), specialised oncology network (Oncacare), In-home clinical services (formerly Symphony Clinical Research) with PRA’s paediatric site network, together with the Clinical Research Units of both organisations, will provide clients with enhanced access to a larger global pool of more diverse patients.
Emerging therapies: ICON offers deep experience in the unique challenges of developing emerging treatments such as Immuno-oncology and other Cell and Gene Therapies, with several approved treatments already on the market. The strengthened therapeutic and scientific capabilities of ICON will help clients to accelerate the delivery of the most complex development programmes.